Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Alternative lengthening of telomere-based immortalization renders H3G34R -mutant diffuse hemispheric glioma hypersensitive to PARP inhibitor combination regimens.
Laemmerer A, Lehmann C, Mayr L, Bruckner K, Gabler L, Senfter D, Meyer P, Balber T, Pirker C, Jaunecker CN, Kirchhofer D, Vician P, Griesser M, Spiegl-Kreinecker S, Schmook MT, Traub-Weidinger T, Kuess P, Eckert F, Federico A, Madlener S, Stepien N, Robl B, Baumgartner A, Hainfellner JA, Dieckmann K, Dorfer C, Roessler K, Corsini NS, Holzmann K, Schmidt WM, Peyrl A, Azizi AA, Haberler C, Beck A, Pfister SM, Schueler J, Loetsch-Gojo D, Knoblich JA, Berger W, Gojo J. Laemmerer A, et al. Among authors: peyrl a. Neuro Oncol. 2024 Nov 18:noae228. doi: 10.1093/neuonc/noae228. Online ahead of print. Neuro Oncol. 2024. PMID: 39556024
Feasibility, tolerability, and first experience of intracystic treatment with peginterferon alfa-2a in patients with cystic craniopharyngioma.
Hedrich C, Patel P, Haider L, Taylor T, Lau E, Hook R, Dorfer C, Roessler K, Stepien N, Lippolis MA, Schned H, Koeller C, Mayr L, Azizi AA, Peyrl A, Lopez BR, Lassaletta A, Bennett J, Gojo J, Bartels U. Hedrich C, et al. Among authors: peyrl a. Front Oncol. 2024 Jul 10;14:1401761. doi: 10.3389/fonc.2024.1401761. eCollection 2024. Front Oncol. 2024. PMID: 39050573 Free PMC article.
Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
Peyrl A, Chocholous M, Sabel M, Lassaletta A, Sterba J, Leblond P, Nysom K, Torsvik I, Chi SN, Perwein T, Jones N, Holm S, Nyman P, Mörse H, Öberg A, Weiler-Wichtl L, Leiss U, Haberler C, Schmook MT, Mayr L, Dieckmann K, Kool M, Gojo J, Azizi AA, André N, Kieran M, Slavc I. Peyrl A, et al. JAMA Oncol. 2023 Dec 1;9(12):1688-1695. doi: 10.1001/jamaoncol.2023.4437. JAMA Oncol. 2023. PMID: 37883081 Free PMC article. Clinical Trial.
72 results